Bora Pharmaceuticals expands presence in CDMO sector

Bora Pharmaceuticals, a contract development and manufacturing organization (CDMO), announced a partnership with Taishin Healthcare Limited (Taishin Holdings), a holding firm that offers financial services. The two parties will jointly invest up to $108 million to target forward-looking CDMOs and contract research organizations (CROs).

Bora plans to grow its presence in the CDMO sector by deploying private equity funds and its existing resources. The company says that as a result of the agreement, it will be able to enter the macromolecular/cell and gene therapy manufacturing space, while also driving the development of Taiwan's CDMO field.

"Given the global Covid-19 pandemic, the interest among global investors in investment in and acquisition of biotech pharmaceutical companies has been enhanced,” noted Bobby Sheng, chairman of Bora Pharmaceuticals. "In order to effectively allocate resources, international pharmaceutical makers have moved towards specialization over the past few years, resulting in CDMO services becoming a trend sweeping the global biotech pharmaceutical sector.”